Efficacy and safety of dexamethasone combined with recombinant human thrombopoietin in the treatment of idiopathic thrombocytopenic purpura
Objective To analyze the efficacy and safety of dexamethasone combined with recombinant human thrombopoietin in the treatment of idiopathic thrombocytopenic purpura(ITP).Methods 60 patients with ITP were selected and divided into an observation group and a control group according to random numerical table,with 30 cases in each group.The observation group was treated with dexamethasone and recombinant human thrombopoietin,and the control group was treated with dexamethasone alone.The clinical efficacy,platelet count and occurrence of adverse reactions were compared between the two groups.Results The total effective rate was 93.33%in the observation group and 73.33%in the control group;the total effective rate of the observation group was significantly higher than that of the control group(P<0.05).The platelet counts before and after treatment were(7.52±2.14)×109/L and(123.11±25.82)×109/L in the observation group,and(7.51±2.04)×109/L and(75.43±15.77)×109/L in the control group.After treatment,the platelet count in both groups was higher than that before treatment,and the platelet count in the observation group was significantly higher than that in the control group(P<0.05).The incidence of adverse reactions were 10.00%and 16.67%in the observation group and the control group;the incidence of adverse reactions in the observation group was slightly lower than that in the control group,but the difference was not statistically significant(P>0.05).Conclusion Dexamethasone combined with recombinant human thrombopoietin in the treatment of ITP has good efficacy and safety,and can be used as an effective treatment.
DexamethasoneRecombinant human thrombopoietinIdiopathic thrombocytopenic purpuraSafety
NETL
NSTL
万方数据
